MindRank's novel dual WEE1/YES1 kinase inhibitor MRANK-106 received FDA IND clearance for treatment of multiple advanced solid tumors, with Phase I trials set to begin in 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.